BeiGene Shares Rise 7% After European Approval of Tislelizumab Cancer Treatment
By Chris Wack
BeiGene shares were up 7% to $139.39 after the company said the European Commission has approved tislelizumab as a treatment for non-small cell lung cancer across multiple tumor types.
The approved indications for tislelizumab are, in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of adult patients with squamous non-small cell lung cancer. It also can be used as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer after prior platinum-based therapy.
BeiGene plans to combine the non-small cell lung cancer indications with the second-line indication under the brand name Tevimbra, which will launch in the first EU countries later in 2024. Tevimbra is approved in the U.S. and EU after prior chemotherapy.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 23, 2024 10:58 ET (14:58 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits